Skip to main content

Advertisement

Table 1 Serum tumor markers in bilharzial and non-bilharzial bladder cancer patients compared to normal (unaffected) patients

From: Levels of certain tumor markers as differential factors between bilharzial and non-biharzial bladder cancer among Egyptian patients

Parameters Control Bilharzial bladder cancer patients non-bilharzial bladder cancer patients ANOVA P <
1. XO (μmol uric acid/min/ml) LSD 0.3 ± 0.05 (2,3) 2.77 ± 0.33 (1,3) 1.58 ± 0.23 (1,2) P < 0.0001
2. Fructosamine (μmol/L) LSD 337.88 ± 34.4 (2,3) 1145.27 ± 146.16 (1,3) 742.3 ± 132.44 (1,2) P < 0.0001
3. hydroxylproline (μg/ml) LSD 23.35 ± 2.83 (2,3) 78.56 ± 10.48 (1,3) 46.06 ± 4.28 (1,2) P < 0.0001
4. IgE (IU/ml) LSD 44.37 ± 1.66 (2,3) 301.49 ± 14.04 (1,3) 269.0 ± 7.66 (1,2) P < 0.0001
5. TNF- (Pg/ml) LSD 7.8 ± 0.22 (2,3) 37.7 ± 1.61 (1,3) 24.6 ± 0.84 (1,2) P < 0.0001
  1. Data are represented as mean ± SD of 10 control and 30 patients (15 patients bilharzial and 15 non-bilharzial)